DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
出版年份 2019 全文链接
标题
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
作者
关键词
-
出版物
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-08-27
DOI
10.1111/jcmm.14609
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The anti-tumor effect of regorafenib in lung squamous cell carcinoma in vitro
- (2018) Xiu Hu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
- (2018) Zheng-Hai Tang et al. CANCER LETTERS
- STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
- (2018) Federica Laudisi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics
- (2018) Dnyandev B. Jarhad et al. JOURNAL OF MEDICINAL CHEMISTRY
- Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer
- (2018) Edward B. Garon et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives
- (2018) Fernanda Neumann et al. Scientific Reports
- Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine
- (2018) Manendra Babu Lankadasari et al. Theranostics
- STAT3 regulatedmiR-216apromotes ovarian cancer proliferation and cisplatin resistance
- (2018) Pengfei Jin et al. BIOSCIENCE REPORTS
- STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer
- (2018) Lei Wang et al. CANCER SCIENCE
- Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
- (2018) Seulki Kim et al. Cancer Research and Treatment
- Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature
- (2017) Thu Lan Nguyen et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Novel EGFR (T790M)-cMET dual inhibitors: putative therapeutic agents for non-small-cell lung cancer
- (2017) Pankaj Kumar Singh et al. Future Medicinal Chemistry
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
- (2017) Ahmad A. Zulkifli et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
- (2017) Judith Raimbourg et al. MOLECULAR CANCER THERAPEUTICS
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
- (2017) David J. Heineman et al. Therapeutic Advances in Medical Oncology
- Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
- (2017) Ju Hwan Cho Immune Network
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
- (2016) Jianlin Xu et al. LUNG CANCER
- Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition
- (2016) Yang-ling Li et al. MEDICAL ONCOLOGY
- Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
- (2016) Toshimitsu Yamaoka et al. MOLECULAR CANCER THERAPEUTICS
- TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
- (2016) D-W Wu et al. Cell Death & Disease
- Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
- (2015) Bin-Chi Liao et al. CURRENT OPINION IN ONCOLOGY
- DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model
- (2015) N. Kurabayashi et al. EMBO REPORTS
- A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologiesin vitro
- (2015) Séverine Coutadeur et al. JOURNAL OF NEUROCHEMISTRY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma
- (2014) HIROKO MATAKI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737
- (2014) Chong Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth
- (2014) Sung Keun Jung et al. MOLECULAR CARCINOGENESIS
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
- (2013) Natividad Pozo et al. JOURNAL OF CLINICAL INVESTIGATION
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- (2013) Balázs Győrffy et al. PLoS One
- DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1
- (2010) Xiumei Guo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A
- (2010) Yasushi Ogawa et al. Nature Communications
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More